Keros Therapeutics (NASDAQ:KROS) Stock Rating Reaffirmed by Piper Sandler
Keros Therapeutics (NASDAQ:KROS – Get Free Report)‘s stock had its “overweight” rating reissued by equities research analysts at Piper Sandler in a research report issued on Wednesday, Benzinga reports. They currently have a $105.00 price objective on the stock. Piper Sandler’s target price suggests a potential upside of 58.61% from the stock’s previous close. A […]
More Stories
Michael Cohen’s Former Legal Adviser Disputes His Trump Trial Allegations
By Jack Phillips A former lawyer who once advised Michael Cohen testified in Congress on May 15 that some of...
The Inflation Tax Wrecking America
By Jeffrey A. Tucker Tired of it yet? Month after month, now going on more than three years, muckety-mucks with...
DNA in Pfizer COVID-19 Vaccine Is ‘Several Hundred Times’ Over Limit: Report
By Naveen Athrappully DNA contamination in Pfizer’s COVID-19 vaccines was found to be hundreds of times higher than permissible limits,...
California Leads the Nation in Job Losses: Federal Data
By Bill Pan California currently leads the nation in job losses, with a recent wave of layoffs particularly hitting the...
Leonardo AI Review: Comprehensive Guide to AI-Generated Art Creation Tool
With generative AI taking the internet into storm, several tools have been introduced to the world. One of them is...
School Spirits Season 2 To Explore Maddie’s Journey Towards Her Truth
School Spirits is an American drama. Its first season concluded last year. This article discusses whether or not the show...